August 31, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Notice of Appointment of Corporate Officer
TOKYO, Japan, August 30, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, the“Company” or “SymBio”) today announced the appointment of a corporate officer by the Board ofDirectors on August 30, 2022.
Appointment of Corporate Officer
Effective on October 1, 2022, the Company established the Global BCV Business Unit, and appointed
Mr. Kei Bamba as Corporate Officer and Head of the Global BCV Business Unit.
By establishing the Global BCV Business Unit, the Company aims to develop a more agile global
business by building a seamless process from research & development to commercialization.
Statement from Mr. Fuminori Yoshida, President and CEO of SymBio: “For the Company, thesuccessful development and commercialization of BCV means the globalization of our business.
We expect that the establishment of Global BCV Business Unit, which is an integrated system, will
provide a strong driving force for the globalization of the business.”
1.

Newly appointed Corporate Officer
NameKei Bamba

Title
Corporate Officer, Head of Global BCVBusiness Unit

2.

Date of Appointment: October 1, 2022

3.

Profile of the newly appointed Corporate Officer
April 1999

Pfizer Japan Inc.: Started in the Sales Division, Director ofMarketing Excellence in Products Business Unit and otherposition

November 2013

Eli Lilly Japan Inc.: Director of Marketing in BioMedicines
Business Unit
1

March 2017

Bristol-Myers Squibb Inc.: Director of Sales in Specialty
Business Unit

July 2018

GlaxoSmithKline Inc.: Corporate Officer, Head, Specialty Care
Business Unit

April 2022

Amgen Inc.: Corporate Officer, Executive Director, Head,
Specialty Care Business Unit

October 2022

Joined SymBio Pharmaceuticals Limited as Head of Global
BCV Business Unit.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About the Anti-viral Drug Brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved
and marketed in the United States and the European Union, but unapproved in Japan. As BCV
exhibits not only higher anti-viral activity, but also a superior characteristics profile in comparison
with CDV and other antiviral drugs, BCV is expected to be an effective treatment against a widespectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV),
Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is expected to be a highly
active antimultiviral agent that can reduce the risk of nephrotoxicity or myelosuppression, which areserious side effects of other antiviral drugs including CDV. SymBio entered into an exclusive global
license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir(BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive
worldwide rights to develop, manufacture, and commercialize BCV in all human indications,excluding the prevention and treatment of orthopox infections (which includes smallpox andmonkeypox).
The Company is expanding its business aiming to become a global specialty pharmaceutical company
by 2030. To maximize business value, the Company is currently conducting a global Phase II clinical
trial mainly in the U.S. for patients with adenovirus infection after hematopoietic stem celltransplantation, and initiated a global Phase II clinical trial mainly in Australia, Japan, and South
Korea for patients with BK virus infection after kidney transplantation in June 2022.
In addition to its high antiviral activity, BCV is also expected to have anti-tumor effects, and we are
currently conducting joint research with the National Cancer Center of Singapore, the University of2

California, San Francisco, and Brown University in the U.S. to confirm BCV’s anti-cancer activity andsynergistic effects when combined with its antiviral activity. Furthermore, the Company has initiateda study to evaluate the potential antiviral activity of BCV against EBV in collaboration with theNational Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health(NIH) in the U.S.

3